EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA‐dependent RNA polymerase using molecular modeling approach

Mansi Dutt, Anuj Kumar iD, Madhusmita Rout, Budheswar Dehury iD, Gustavo Martinez, Pacifique Ndishimye, Alyson A Kelvin, David J Kelvin

Journal of Cellular Biochemistry · 2023

DOI: 10.1002/jcb.30397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2023. Verfasst von Mansi Dutt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Department of Paediatrics, IWK Health Center, Canadian Centre for Vaccinology (CCfV), Faculty of Medicine,…. Hauptthemen laut MEDLINE: Drug Repositioning, Mpox, Monkeypox. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Dalhousie Medical Research Foundation, Li Ka Shing Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mpox (formerly Monkeypox), a zoonotic illness caused by the Mpox virus, belongs to the Orthopoxvirus genus in the family Poxviridae. To design and develop effective antiviral therapeutics against DNA viruses, the DNA‐dependent RNA polymerase (DdRp) of poxviruses has emerged as a promising drug target. In the present study, we modeled the three‐dimensional (3D) structure of DdRp using a template‐based homology approach. After modeling, virtual screening was performed to probe the molecular interactions between 1755 Food and Drug Administration‐approved small molecule drugs (≤500 molecular weight) and the DdRp of Mpox. Based on the binding affinity and molecular interaction patterns, five drugs, lumacaftor (−11.7 kcal/mol), conivaptan (−11.7 kcal/mol), betulinic acid (−11.6 kcal/mol), fluspirilene (−11.3 kcal/mol), and imatinib (−11.2 kcal/mol), have been ranked as the top drug compounds interacting with Mpox DdRp. Complexes of these shortlisted drugs with DdRp were further evaluated using state‐of‐the‐art all‐atoms molecular dynamics (MD) simulations on 200 nanoseconds followed by principal component analysis (PCA). MD simulations and PCA results revealed highly stable interactions of these small drugs with DdRp. After due validation in wet‐lab using available in vitro and in vivo experiments, these repurposed drugs can be further utilized for the treatment of contagious Mpox virus. The outcome of this study may establish a solid foundation to screen repurposed and natural compounds as potential antiviral therapeutics against different highly pathogenic viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningMpox, MonkeypoxHumansDNA-Directed RNA PolymerasesMolecular Dynamics SimulationAntiviral AgentsMolecular Docking Simulation

Stichwörter der Autor:innen

DNA-dependent RNA polymerase (DdRp)Mpox virushomology modelingmolecular dynamics simulationssmall moleculesvirtual screening

Substanzen

DNA-Directed RNA PolymerasesAntiviral Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Department of Paediatrics, IWK Health Center, Canadian Centre for Vaccinology (CCfV), Faculty of Medicine, Dalhousie University, Halifax, Canada.
  • European Virus Bioinformatics Center, Jena, Germany.
  • Bioinformatics Division, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
  • Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

ORCID-Profile: Anuj Kumar, Budheswar Dehury

Förderung

  • CIHR
  • Dalhousie Medical Research Foundation
  • Li Ka Shing Foundation
  • Canadian Institutes of Health Research

Zitieren

APA

Dutt, M., Kumar, A., Rout, M., Dehury, B., Martinez, G., Ndishimye, P., Kelvin, A. A., & Kelvin, D. J. (2023). Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA‐dependent RNA polymerase using molecular modeling approach. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30397

Vancouver

Dutt M, Kumar A, Rout M, Dehury B, Martinez G, Ndishimye P, et al. Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA‐dependent RNA polymerase using molecular modeling approach. Journal of Cellular Biochemistry. 2023. doi:10.1002/jcb.30397

BibTeX
@article{Dutt2023,
  author = {Dutt, Mansi and Kumar, Anuj and Rout, Madhusmita and Dehury, Budheswar and Martinez, Gustavo and Ndishimye, Pacifique and Kelvin, Alyson A and Kelvin, David J},
  title = {Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA‐dependent RNA polymerase using molecular modeling approach},
  journal = {Journal of Cellular Biochemistry},
  year = {2023},
  doi = {10.1002/jcb.30397}
}
Kostenlos starten →